Delivering results in under an hour, Sysmex’s PA-100 AST System drastically cuts diagnosis and treatment times for UTIs. A recent financial analysis based on Spanish healthcare data points to significant cost-saving potential. Recipient of the £8 million Longitude Prize, the system is a vital advancement in the fight against antimicrobial resistance.
Sysmex has introduced a groundbreaking solution in the diagnosis and management of uncomplicated urinary tract infections. The PA-100 AST System employs sophisticated nanofluidic technology alongside rapid antimicrobial susceptibility testing (AST) to produce reliable results within 45 minutes. In contrast to traditional diagnostics, this fast turnaround supports immediate, informed clinical decisions, improving outcomes for patients.
UTIs: A widespread global health burden
Urinary tract infections affect over 400 million people globally each year, making them one of the most common bacterial infections. Delayed diagnoses and reliance on broad, empirical treatments frequently result in complications and contribute to rising antimicrobial resistance (AMR). The PA-100 AST System tackles these challenges by delivering high sensitivity (84%) and specificity (99%), supporting accurate treatment decisions while reducing the use of broad-spectrum antibiotics — a key factor in managing AMR.
Alain Baverel, President & CEO Sysmex Europe SE, remarked,
“The PA-100 AST System represents a pivotal innovation in the fight against antimicrobial resistance. By providing clinicians with rapid and precise diagnostic insights, we can transform how urinary tract infections are treated globally. This tool not only benefits patients but also strengthens the financial sustainability of healthcare systems.”
Health economics model signals major savings in Spain
A recent budget impact analysis has projected considerable savings for Spain’s public health sector through the adoption of the PA-100 AST System. Assuming full-scale implementation, cost reductions could reach €323 million in the first year. These savings are linked to reduced hospital admissions, fewer complications, and decreased productivity losses, with further reductions expected over three years.
Takashi Ono, Member of the Managing Board and Senior Executive Officer & Managing Director of Sysmex Corporation, commented,
“By addressing one of the leading causes of antibiotic misuse, Sysmex’s PA-100 AST System aligns perfectly with global efforts to combat antimicrobial resistance. The system empowers healthcare providers with the data needed to make the right decision at the right time, benefiting patients and public health alike.”
Award-winning technology recognised for global impact
Highlighting its significance in tackling antimicrobial resistance, the PA-100 AST System was awarded the prestigious Longitude Prize — a £8 million award for pioneering solutions to AMR. The recognition affirms the system’s potential to drive meaningful change in both patient care and public health strategies.
Rapid, reliable results with compact design
Using a compact cartridge no larger than a smartphone, the PA-100 AST System can detect bacteriuria in just 15 minutes and identify effective antibiotics in the following 30 minutes. The technology enables prompt treatment decisions and helps prevent complications from delayed care.
